FDA Law Blog: Biosimilars

SEPTEMBER 27, 2023

The meeting package for Type D meetings should be included with the meeting request. FDA intends to provide preliminary responses to Type D meeting packages no later than 5 calendar days before the meeting date. The goal for meeting minutes is the same as all other meeting types – 30 days after the meeting.

Packaging 64

Packaging Drug Development Documentation 64

Pharmaceutical Technology

SEPTEMBER 8, 2022

The companies offer various solid dose products and services including, but not limited to, formulation and analytical development, manufacturing capabilities, technology transfer and scale-up, quality and regulatory support, commercial manufacturing, packaging, and warehousing.

Dosage 40

Dosage Packaging Documentation Pharmaceutical Companies 40

pharmaphorum

JANUARY 18, 2022

Who should Attend: Drug-delivery developers. Primary Packaging material designers. Secondary packagers. Smart device developers. Training device developers. Drug developers. Understand requirements to facilitate the documentation preparation needed to obtain a NB Opinion.

Packaging 52

Packaging Documentation Vaccines Drug Development 52

Pharmaceutical Technology

SEPTEMBER 23, 2022

And, because it also manufactures products, its staff is current on regulatory requirements and FDA/ICH Guidance documents. Since CDMOs have different material handling capabilities, when choosing a partner, it’s important to understand if the drug will involve a controlled substance, hormone, small molecule or biological.

Packaging 59

Packaging Controlled Substances Documentation Pharmaceutical Companies 59

FDA Law Blog: Biosimilars

NOVEMBER 2, 2023

CBER may still request additional information when deemed appropriate, but the stated hope is that increased use of VCS can facilitate product development by reducing the need to develop unique methods for individual products and that they will typically reduce the amount of necessary documentation “and may reduce FDA review time.”

Packaging 59

Packaging Documentation Labelling Communication 59

European Pharmaceutical Review

JANUARY 13, 2025

3 Encouragingly, there are many examples of the life sciences sector seeking to embrace sustainable drug development; reconciling the drive for innovation with the need to reduce waste and emissions produced during the R&D process, as well as throughout the product lifecycle. 5 However, the benefits are well documented.

Packaging 52

Packaging Community Pharmacies Documentation Pharmaceutical Companies 52

Quality Matters

JUNE 6, 2023

Despite being called “inactive” ingredients, excipients in medicines play a vital role in drug development, delivery, effectiveness, and stability. Comprising up to 90% of individual drug products, excipients function as binders, disintegrants, solubilizers, coatings, preservatives, colors, and flavorings.

Dosage 52

Dosage Packaging Documentation Drug Development 52

Pharmaceutical Technology

NOVEMBER 28, 2022

We source as much of the materials as we possibly can locally, even packaging,” he notes. When we need new packaging, it is really simple to get and it is quick. To learn more about the development and partnership opportunities for businesses within Scotland’s health sector, download the document on this page.

Hospitals 52

Hospitals Packaging Medical Schools Documentation 52

FDA Law Blog: Biosimilars

DECEMBER 6, 2024

As much of the content of this draft guidance for cellular and gene therapy (CGT) products is articulated elsewhere, this document serves as a one-stop shop or Cliffs Notes for the numerous guidance documents now covering CGT product development. CBER will not commit to reviewing packages greater than 250 pages.

Documentation 59

Documentation Packaging Clinical Pharmacology Drug Development 59